Salt Lake City, UT1 Active Studies

Parkinsons Disease Clinical Trials in Salt Lake City, UT

Find 1 actively recruiting parkinsons disease clinical trials in Salt Lake City, UT. Connect with local research sites and explore new treatment options.

1
Active Trials
1
Sponsors
200
Enrolling

Recruiting Parkinsons Disease Studies in Salt Lake City

About Parkinsons Disease Clinical Trials in Salt Lake City

Parkinson's disease is a progressive nervous system disorder that affects movement, causing tremors, stiffness, and difficulty with balance. It results from the loss of dopamine-producing neurons in the brain. Treatment includes medications, deep brain stimulation, and emerging therapies targeting disease modification.

There are currently 1 parkinsons disease clinical trials recruiting participants in Salt Lake City, UT. These studies are seeking a combined 200 participants. Research is being sponsored by Boston University Charles River Campus. Clinical trial participation is free and participants receive study-related medical care at no cost.

Parkinsons Disease Clinical Trials in Salt Lake City — FAQ

Are there parkinsons disease clinical trials in Salt Lake City?

Yes, there are 1 parkinsons disease clinical trials currently recruiting in Salt Lake City, UT. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Salt Lake City?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Salt Lake City research site will contact you about next steps.

Are clinical trials in Salt Lake City free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Salt Lake City studies also compensate for your time and travel.

What parkinsons disease treatments are being tested?

The 1 active trials in Salt Lake City are testing new therapies including novel drugs, biologics, and treatment approaches for parkinsons disease.

Data updated October 12, 2026 from ClinicalTrials.gov